Laprysta

Lacosamide, the active ingredient in Laprysta, is an anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset seizures and epilepsy in adults and is used as adjunctive therapy when seizure control is insufficient with other medications.

GNH USA supplies Laprysta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Laprysta (lacosamide) is indicated for seizure disorders within the epilepsy disease family.

Partial‑onset seizures: Reduces the frequency of focal seizures when added to existing antiepileptic regimens. Epilepsy (refractory): Provides additional seizure control for patients whose epilepsy is not fully managed by other drugs. Adjunctive therapy in focal epilepsy: Enhances overall seizure management as part of combination therapy.

Lacosamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness - Nausea - Headache - Fatigue - Blurred vision - Diplopia

Serious or Rare Side Effects: - Suicidal ideation or behavior - Cardiac conduction abnormalities (e.g., PR‑interval prolongation) - Severe skin reactions such as Stevens‑Johnson syndrome - Hypersensitivity reactions including anaphylaxis - Elevated liver enzymes - Respiratory depression in susceptible individuals

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: Adjust dosing and monitor renal function. - Hepatic impairment: Use with caution and monitor liver enzymes. - Cardiac conduction: Obtain baseline ECG and monitor for PR‑interval changes. - Pregnancy: Potential risk unknown; discuss benefits and risks with the prescriber. - Concomitant CNS depressants: May increase sedation and respiratory depression. - Store at ambient temperature: Keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): May markedly lower lacosamide plasma concentrations. - Co‑administration with other sodium‑channel blockers: Increases risk of cardiac conduction disturbances.

Moderate Interactions (Monitor Closely): - Carbamazepine: Can raise lacosamide levels, necessitating dose adjustment. - Anticoagulants (e.g., warfarin): May alter bleeding risk; monitor coagulation parameters. - Alcohol: Enhances central nervous system depression; advise limited intake.